Must Watch These 5 Stocks: Pfizer Inc. (NYSE:PFE), Esperion Therapeutics (NASDAQ:ESPR), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Verisk Analytics (NASDAQ:VRSK), Arotech (NASDAQ:ARTX)

On 15 January Pfizer Inc. (NYSE:PFE) stepping up research on drugs that use the immune system to attack tumors, seeking to catch up to Merck & Co. and Bristol-Myers Squibb Co. (BMY) in one of the industry‚Äôs most promising categories. On Wednesday shares of Pfizer Inc. (NYSE:PFE) closed at $32.64. Company’s sales growth for last 5 years was 1.30% and EPS growth for next 5 years is recorded as 1.35%.

On January 12, 2015, Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced the submission to FDA of the responses to the PPAR and 240 mg Partial Clinical Holds for ETC-1002. In 2009, upon submission of the original IND for ETC-1002, the FDA had determined that ETC-1002 was a potential peroxisome proliferator activated receptor (PPAR) agonist and as a result was subject to a partial clinical hold. Esperion Therapeutics, Inc. (NASDAQ:ESPR) in last trading activity moved down -0.53% to close at $45.43. Company weekly performance is 0.40% while its quarterly performance stands at 105.66%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is -8.50% away from its 52 week high.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced on 8 January that its partner Melinta Therapeutics reported positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to evaluate delafloxacin, an investigational fluoroquinolone, compared with vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). On last trading day Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) advanced 0.05% to close at $54.76. Its volatility for the week is 4.01% while volatility for the month is 4.28%. LGND’s sales growth for past 5 years was 12.40% and its EPS growth for past 5 years was 15.70%. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) monthly performance is 5.05%.

Deutsche Bank reissued their hold rating on shares of Verisk Analytics (NASDAQ:VRSK) in a research report released on Wednesday morning. Deutsche Bank currently has a $66.00 price objective on the stock, down from their previous price objective of $67.00. Verisk Analytics, Inc. (NASDAQ:VRSK) has 0.10% insider ownership while its institutional ownership stands at 92.70%. In last trading activity company’s stock closed at $63.43.

Arotech Corporation (NASDAQ:ARTX) Power Systems Division on 12 January has received $17 million in new orders for batteries and power systems. On last trading day Arotech Corporation (NASDAQ:ARTX) advanced 0.43% to close at $2.36. Its volatility for the week is 5.35% while volatility for the month is 6.10%. ARTX’s sales growth for past 5 years was 5.20% and its EPS growth for past 5 years was 19.50%. Arotech Corporation (NASDAQ:ARTX) monthly performance is 0.43%.

Leave a Reply

Your email address will not be published. Required fields are marked *

*